Referred to the Committee on Energy and Commerce, and in addition to the Committees on Education and Workforce, and Ways and Means, for a period to be subsequently determined by t…
The bill (H.R. 5139) requires group health plans and health insurance issuers offering group or individual coverage to cover FDA‑approved epinephrine delivery systems (including auto‑injectors, nasal spray, and sublingual systems). For in‑network coverage the bill bars application of any deductible and caps cost sharing at $60 per package of two delivery systems (or equivalent); any cost‑sharing paid counts toward plan deductibles and out‑of‑pocket maximums.
Scope and acceptability of a federal mandate on plan design: liberals view it as necessary consumer protection; conservatives see it as federal overreach.
Relative to its intended legislative type, this bill clearly creates a substantive coverage obligation with specific cost‑sharing limits and integrates those obligations into the PHSA, ERISA, and IRC with an explicit effective date.
The bill (H.R. 5139) requires group health plans and health insurance issuers offering group or individual coverage to cover FDA‑approved epinephrine delivery systems (including auto‑injectors, nasal spray, and sublingual systems).
For in‑network coverage the bill bars application of any deductible and caps cost sharing at $60 per package of two delivery systems (or equivalent); any cost‑sharing paid counts toward plan deductibles and out‑of‑pocket maximums.
Plans are not required to cover epinephrine devices provided by out‑of‑network providers and may impose higher cost sharing for out‑of‑network delivery.
On substance the bill is narrow, concrete, and administratively implementable, which increases its prospects relative to sweeping reforms. However, it creates a new federal coverage mandate affecting insurers and employer plans and touches on drug/device pricing—areas where industry stakeholders can mobilize opposition. The lack of explicit federal funding or complex implementation may help, but getting broad Senate agreement and navigating committee priorities remain significant obstacles.
Relative to its intended legislative type, this bill clearly creates a substantive coverage obligation with specific cost‑sharing limits and integrates those obligations into the PHSA, ERISA, and IRC with an explicit effective date. The draft is strong on the core rule and definition of covered products but limited on implementation mechanics, fiscal acknowledgment, enforcement language, and handling of operational edge cases.
Scope and acceptability of a federal mandate on plan design: liberals view it as necessary consumer protection; conservatives see it as federal overreach.
These are examples from the analysis, not a ranked list of the most-affected groups.
Scope and acceptability of a federal mandate on plan design: liberals view it as necessary consumer protection; conservatives see it as federal overreach.
A mainstream liberal would generally view this bill positively as a targeted consumer protection that increases affordability and access to a life‑saving medication.
They would see the ban on deductibles and the $60 cap as meaningful steps to reduce financial barriers for people with severe allergies.
They might critique the cap as higher than ideal and press for zero cost sharing, broader device inclusions, stronger enforcement language, and coverage for out‑of‑network emergencies.
A centrist/ moderate would view the bill as a narrowly targeted consumer protection that addresses a clear problem—high out‑of‑pocket costs for epinephrine injectors—without overhauling the insurance system.
They would appreciate the limited scope (epinephrine delivery systems only) and the attempt to cap cost sharing, but would be attentive to potential cost shifts to insurers, employers, or premiums.
They would want clarity on impacts for self‑insured and small‑employer plans, and might support the bill if accompanied by monitoring, a fiscal estimate, or sunset/review provisions.
A mainstream conservative would acknowledge the goal of improving access to a life‑saving drug but would be critical of a federal mandate that restricts plan design and effectively caps patient cost sharing.
They would view this as federal overreach into employer‑sponsored and private insurance markets, particularly given the ERISA/IRC amendments, and would be concerned about cost burdens shifted to employers, insurers, and ultimately premiums for all enrollees.
They would prefer market‑based solutions, targeted tax incentives, or state‑level reforms rather than a broad federal requirement.
Reached or meaningfully advanced
Reached or meaningfully advanced
Still ahead
Still ahead
Still ahead
On substance the bill is narrow, concrete, and administratively implementable, which increases its prospects relative to sweeping reforms. However, it creates a new federal coverage mandate affecting insurers and employer plans and touches on drug/device pricing—areas where industry stakeholders can mobilize opposition. The lack of explicit federal funding or complex implementation may help, but getting broad Senate agreement and navigating committee priorities remain significant obstacles.
The bill has not accumulated any surfaced votes yet.
Scope and acceptability of a federal mandate on plan design: liberals view it as necessary consumer protection; conservatives see it as fed…
On substance the bill is narrow, concrete, and administratively implementable, which increases its prospects relative to sweeping reforms.…
Relative to its intended legislative type, this bill clearly creates a substantive coverage obligation with specific cost‑sharing limits and integrates those obligations into the PHSA, ERISA, and IRC with an explicit ef…
Go beyond the headline summary with full stakeholder mapping, legislative design analysis, passage barriers, and lens-by-lens tradeoff breakdowns.